Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Spero Therapeutics (SPRO) Income from Non-Controlling Interests (2016 - 2017)

Spero Therapeutics filings provide 2 years of Income from Non-Controlling Interests readings, the most recent being -$6000.0 for Q4 2017.

  • On a quarterly basis, Income from Non-Controlling Interests rose 99.39% to -$6000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was -$1.1 million, a N/A change, with the full-year FY2017 number at -$1.1 million, up 84.01% from a year prior.
  • Income from Non-Controlling Interests hit -$6000.0 in Q4 2017 for Spero Therapeutics, up from -$8000.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of -$6000.0 in Q4 2017 to a low of -$1.6 million in Q3 2016.